Related Experiment Video
Updated: Jun 16, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Hepatoma-targeted gene delivery using a tumor cell-specific gene regulation system combined with a human liver
Jeong-Hun Kang1, Jun Oishi, Jong-Hwan Kim
1Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Fukuoka, Japan.
Abstract:
Hepatoma (hepatocellular carcinoma) is the most common type of malignant tumor originating in the liver and has a relatively low 5-year survival rate. The development of hepatoma-targeted therapy is needed to increase treatment efficiency and to reduce the incidence of undesirable side effects. In this study we developed a novel hepatoma-targeted gene delivery system. The gene delivery system was prepared by combining a human liver cell-specific bionanocapsule (BNC) and a tumor cell-specific gene regulation polymer, which responds to hyperactivated protein kinase C alpha in hepatoma cells. The complex of the polymer-DNA with BNCs was delivered into cells and tissues. The developed system showed increased transfection efficiency and resulted in cell-specific gene expression in hepatoma cells and tissues (HuH-7), but no gene expression in normal human hepatocytes or human epidermoid tumor cells (A431). The combination of a tumor cell-specific gene regulation system responding to protein kinase C alpha and BNCs showed excellent potential for the selective treatment of hepatomas. The system could be a useful method with applications in hepatoma-specific gene therapy and molecular imaging. From the clinical editor: Hepatocellular carcinoma is the most common type of malignant tumor in the liver with a low 5-year survival rate. In this study, a novel hepatoma-targeted gene delivery system was prepared by combining a human liver cell-specific bionanocapsule and a tumor cell-specific gene regulation polymer, which responds to hyperactivated protein kinase C (PKC)a in hepatoma cells. The system could be a useful in hepatoma-specific gene therapy and molecular imaging.
Insights
Researchers developed a novel hepatoma-targeted gene delivery system using bionanocapsules and a polymer responsive to protein kinase C alpha. This system selectively targets liver cancer cells for enhanced gene therapy and molecular imaging.
Area of Science:
- Biomedical Engineering
- Molecular Biology
- Oncology
Background:
- Hepatocellular carcinoma (HCC), a common liver malignancy, has a low 5-year survival rate, necessitating targeted therapies.
- Current treatments for HCC often result in undesirable side effects due to lack of specificity.
- Developing targeted therapeutic strategies is crucial for improving HCC treatment efficiency and patient outcomes.
Purpose of the Study:
- To develop a novel hepatoma-targeted gene delivery system for selective HCC treatment.
- To enhance gene transfection efficiency specifically in liver cancer cells.
- To explore the potential of this system for hepatoma-specific gene therapy and molecular imaging.
Main Methods:
- Constructed a gene delivery system by combining human liver cell-specific bionanocapsules (BNCs) with a tumor cell-specific gene regulation polymer.
- The polymer was designed to respond to hyperactivated protein kinase C alpha (PKCα) present in hepatoma cells.
- Evaluated the system's transfection efficiency and cell-specific gene expression in hepatoma (HuH-7) and control cells (normal hepatocytes, A431).
Main Results:
- The developed BNC-polymer-DNA complex demonstrated increased transfection efficiency in target cells.
- Achieved cell-specific gene expression exclusively in hepatoma cells and tissues (HuH-7).
- Showed no significant gene expression in normal human hepatocytes or human epidermoid tumor cells (A431), confirming selectivity.
Conclusions:
- The novel hepatoma-targeted gene delivery system, combining BNCs and a PKCα-responsive polymer, shows significant potential for selective HCC treatment.
- This system offers a promising approach for hepatoma-specific gene therapy, improving treatment efficacy and reducing side effects.
- The developed system is a valuable tool for both targeted gene therapy and molecular imaging applications in liver cancer.
